Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Cypionate

FDA-approved product (injectable, injection), marketed as Depo-Estradiol, Estradiol Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

    NCT00099437 · start 2005-02-13

    Registered record
    Registry ID
    NCT00099437
    Conditions
    Breast Cancer
    Interventions
    Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2005-02-13
    Completion
    2026-12-31
    Enrolment
    736

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFulvestrant
    PhasePhase 3
    Registry statusActive not recruiting

  • Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

    NCT00146601 · start 2004-06

    Registered record
    Registry ID
    NCT00146601
    Conditions
    Breast Cancer
    Interventions
    Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-06
    Completion
    2007-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFulvestrant
    PhasePhase 2
    Registry statusCompleted

  • Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle

    NCT00204438 · start 2002-02

    Registered record
    Registry ID
    NCT00204438
    Conditions
    Contraception
    Interventions
    0.15mg desogestrel /0.03mg ethinyl estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-02
    Completion
    2002-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    Intervention0.15mg desogestrel /0.03mg ethinyl estradiol
    PhaseNot applicable
    Registry statusCompleted

  • Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

    NCT00003771 · start 1997-09

    Registered record
    Registry ID
    NCT00003771
    Conditions
    Breast Cancer; Menopausal Symptoms
    Interventions
    therapeutic estradiol; norethindrone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-09
    Completion
    2004-02
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Menopausal Symptoms
    Interventiontherapeutic estradiol; norethindrone acetate
    PhasePhase 3
    Registry statusCompleted

  • Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    NCT00021372 · start 1996-02

    Registered record
    Registry ID
    NCT00021372
    Conditions
    Lymphoma
    Interventions
    estramustine phosphate sodium; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-02
    Completion
    2006-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionestramustine phosphate sodium; paclitaxel
    PhasePhase 2
    Registry statusCompleted